News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
She has held senior positions at Coca-Cola in China and PepsiCo in India
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Subscribe To Our Newsletter & Stay Updated
